9F21 image
Deposition Date 2024-04-20
Release Date 2025-04-16
Last Version Date 2025-04-16
Entry Detail
PDB ID:
9F21
Keywords:
Title:
Crystal structure of Borrelia burgdorferi CspZ-YACS
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
1.95 Å
R-Value Free:
0.25
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Complement regulator-acquiring surface protein 2 (CRASP-2)
Gene (Uniprot):cspZ
Mutations:Tyr207Ala; Tyr211Ala; Cys187Ser
Chain IDs:A
Chain Length:221
Number of Molecules:1
Biological Source:Borreliella burgdorferi B31
Ligand Molecules
Primary Citation
Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine.
Nat Commun 16 2898 2898 (2025)
PMID: 40189575 DOI: 10.1038/s41467-025-58182-x

Abstact

Borrelia burgdorferi (Bb) causes Lyme disease (LD), one of the most common vector-borne diseases in the Northern Hemisphere. Here, we solve the crystal structure of a mutated Bb vaccine antigen, CspZ-YA that lacks the ability to bind to host complement factor H (FH). We generate point mutants of CspZ-YA and identify CspZ-YAI183Y and CspZ-YAC187S to trigger more robust bactericidal responses. Compared to CspZ-YA, these CspZ-YA mutants require a lower immunization frequency to protect mice from LD-associated inflammation and bacterial colonization. Antigenicity of wild-type and mutant CspZ-YA proteins are similar, as measured using sera from infected people or immunized female mice. Structural comparison of CspZ-YA with CspZ-YAI183Y and CspZ-YAC187S shows enhanced interactions of two helices adjacent to the FH-binding sites in the mutants, consistent with their elevated thermostability. In line with these findings, protective CspZ-YA monoclonal antibodies show increased binding to CspZ-YA at a physiological temperature (37 °C). In summary, this proof-of-concept study applies structural vaccinology to enhance intramolecular interactions for the long-term stability of a Bb antigen while maintaining its protective epitopes, thus promoting LD vaccine development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures